pocketful logo light
pocketful logo light
Astec Lifesciences Ltd logo

Astec Lifesciences Ltd

NSE: ASTEC BSE: 533138

â‚ą770.95

(1.27%)

Wed, 10 Jun 2026, 09:21 am

mtf coin illustrationMTF 5x

Astec Lifesciences Analysis

dividend

thumbs up icon

Pros

    thumbs up icon

    Cons

    • Astec LifeSciences is not paying a notable dividend for India, therefore no need to check if the payments are increasing.
    • No need to calculate the sustainability of Astec LifeSciences's dividends as it is not paying a notable one for India.
    • Astec LifeSciences is not paying a notable dividend for India, therefore no need to check if the payments are stable.
    • Astec LifeSciences's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
    • Astec LifeSciences's dividend is below the markets top 25% of dividend payers in India (3.08%).

    future

    thumbs up icon

    Pros

    • Astec LifeSciences's earnings growth is expected to exceed the low risk savings rate of 7.2%.
    • Astec LifeSciences's earnings are expected to exceed the low risk growth rate next year.
    • Performance (ROE) is expected to be above the current IN Chemicals industry average.
    • Astec LifeSciences's revenue growth is expected to exceed the India market average.
    thumbs up icon

    Cons

    • Astec LifeSciences's earnings are expected to grow by 12.7% yearly, however this is not considered high growth (20% yearly).
    • Astec LifeSciences's earnings growth is positive but not above the India market average.
    • Astec LifeSciences's net income is expected to increase but not above the 50% threshold in 2 years time.
    • Astec LifeSciences is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
    • A decline in Astec LifeSciences's performance (ROE) is expected over the next 3 years.
    • Astec LifeSciences's revenue is expected to increase but not above the 50% threshold in 2 years time.
    • Astec LifeSciences's revenue is expected to grow by 10.7% yearly, however this is not considered high growth (20% yearly).

    health

    thumbs up icon

    Pros

    • Astec LifeSciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
    • Astec LifeSciences is profitable, therefore cash runway is not a concern.
    • Astec LifeSciences is profitable, therefore cash runway is not a concern.
    • Debt is well covered by operating cash flow (170.6%, greater than 20% of total debt).
    • Debt is covered by short term assets, assets are 3.4x debt.
    • Astec LifeSciences's cash and other short term assets cover its long term commitments.
    • The level of debt compared to net worth has been reduced over the past 5 years (69.2% vs 40% today).
    • Interest payments on debt are well covered by earnings (EBIT is 5.9x coverage).
    • Astec LifeSciences's level of debt (40%) compared to net worth is satisfactory (less than 40%).
    thumbs up icon

    Cons

    • High level of physical assets or inventory.

    management

    thumbs up icon

    Pros

    • The tenure for the Astec LifeSciences board of directors is about average.
    • Ashok's remuneration is lower than average for companies of similar size in India.
    • Ashok's compensation has been consistent with company performance over the past year, both up more than 20%.
    • The average tenure for the Astec LifeSciences management team is over 5 years, this suggests they are a seasoned and experienced team.
    thumbs up icon

    Cons

    • Astec LifeSciences individual insiders have only sold shares in the past 3 months.

    misc

    thumbs up icon

    Pros

      thumbs up icon

      Cons

      • Astec LifeSciences is covered by less than 3 analysts.
      • Astec LifeSciences has significant price volatility in the past 3 months.

      past

      thumbs up icon

      Pros

      • Astec LifeSciences has delivered over 20% year on year earnings growth in the past 5 years.
      • Astec LifeSciences used its assets more efficiently than the IN Chemicals industry average last year based on Return on Assets.
      • Astec LifeSciences's earnings growth has exceeded the IN Chemicals industry average in the past year (33.1% vs 9.1%).
      thumbs up icon

      Cons

      • Astec LifeSciences's 1-year earnings growth is less than its 5-year average (33.1% vs 41.9%)
      • Astec LifeSciences's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
      • Astec LifeSciences has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).

      value

      thumbs up icon

      Pros

      • Astec LifeSciences's share price is below the future cash flow value, and at a moderate discount (> 20%).
      • Astec LifeSciences's share price is below the future cash flow value, and at a substantial discount (> 40%).
      • 533138 outperformed the Chemicals industry which returned 2.2% over the past year.
      • 533138 outperformed the Market in India which returned -14.5% over the past year.
      • BSE:533138 is up 26% outperforming the Chemicals industry which returned 6.9% over the past month.
      • BSE:533138 is up 26% outperforming the market in India which returned 8% over the past month.
      thumbs up icon

      Cons

      • Astec LifeSciences is overvalued based on assets compared to the IN Chemicals industry average.
      • Astec LifeSciences is poor value based on expected growth next year.
      • Astec LifeSciences is overvalued based on earnings compared to the IN Chemicals industry average.
      • Astec LifeSciences is overvalued based on earnings compared to the India market.